DSSG Group: Lung

Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of the study is to compare the efficacy of Nivolumab and Relatlimab Plus Chemotherapy Vs Pembrolizumab Plus Chemo for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Stage IIB-IIIB (N2) resectable NSCLC

The purpose of this study is to evaluate the efficacy and safety of adding adjuvant durvalumab after neoadjuvant chemo plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Non-squamous Non-small Cell Lung Cancer

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

This study is to see if survival and progression-free survival are better for patients on Pemrolizumab on its own or in combination with Sacituzumab Tirumotecan. Patients will be on the study maintenance treatment for just under 2 years, as long as their cancer is not getting worse or they do not have serious side effects. About 851 people will be in the study in total.

PDL-1 Positive Metastatic NSCLC

A Phase 3 trial of Acasunlimabin combination with pembrolizumab versus docetaxel in subjects with PD-L1 positive metastatic non-small cell lung cancer after treatment with a PD-1/PD-l1 inhibitor and platinum-containing chemotherapy

With  Advanced/Metastatic Non Small Cell Lung Cancer

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).

Metastatic non-small cell lung cancer

The purpose of this phase 3 clinical trial is to measure overall survival (OS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy.

Resected Stage II, IIIA,IIIB (N2) Non-Small Cell Lung Cancer.

The purpose of the study is to measure which of the arms of patients (i.e. patient on the Adjuvant V940 (mRNA-4157) Plus Pembrolizumab or Adjuvant Placebo Plus Pembrolizumab) has a better disease free survival outcome (time from starting the study to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause).

The study will also measure other parameters such as the overall survival of the patients, lung cancer specific survival, if patients experience any adverse events and patients Quality of Life while participating.

Early-Stage (II to IIIA) Non-small Cell Lung Cancer

The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab.

Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab.

The Phase 3 portion of the study compares the efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy